Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy

Susumu Ogawa, Hiroyuki Kobori, Naro Ohashi, Maki Urushihara, Akira Nishiyama, Takefumi Mori, Tsuneo Ishizuka, Kazuhiro Nako, Sadayoshi Ito

Research output: Contribution to journalArticlepeer-review

56 Citations (Scopus)

Abstract

Objective: To demonstrate that the administration of an angiotensin (Ang) II type 1 receptor (AT1R) blocker (ARB) inhibits the vicious cycle of high glucose (HG)-reactive oxygen species (ROS)-angiotensinogen (AGT)-Ang II-AT1R-ROS by suppressing ROSs and inflammation, thus ameliorating diabetic nephropathy (DN). Research Design and Methods: Thirteen hypertensive DN patients were administered ARBs, and the following parameters were evaluated before and 16 weeks after the treatment: urinary AGT (UAGT), albumin (albumin-creatinine ratio: ACR), 8-hydroxydeoxyguanosine (8-OHdG), 8-epi-prostaglandin F2α (8-epi-PGF2α), monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, and IL-10. Results: ARB treatment reduced the blood pressure and urinary levels of AGT, ACR, 8-OHdG, 8-epi-PGF2α, MCP-1, and IL-6 but increased the urinary levels of IL-10. The reduction rate of UAGT correlated with the reduction rate of blood pressure; the reduction rates of the urinary ACR, 8-OHdG, 8-epi-PGF2α, MCP-1, and IL-6 levels; and the increase rate of the urinary IL-10 levels. Moreover, subjects who had high UAGT values at baseline exhibited higher reduction rates of urinary albumin excretion. Conclusions: ARB-induced blockade of the abovementioned vicious cycle contributes to the renoprotective effects of ARBs in DN. The urinary levels of AGT could represent a predictive factor for reduced ACR in patients receiving ARB treatment.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
JournalBiomarker Insights
Volume2009
Issue number4
DOIs
Publication statusPublished - 2009

Keywords

  • Angiotensin II type 1
  • Diabetic nephropathy
  • Receptor blockers

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy'. Together they form a unique fingerprint.

Cite this